Specification

MSDS

TSE / BSE Statement

Retest Statement

• edoxaban, naproxen, patients, bleeding, low-dose, high-dose, pharmacokinetics, renal impairment, impairment, effects, factors, exposure, renal, thrombosis, studies, atrial, clinical, inhibitor, atrial fibrillation, treatment, inhibitors, analysis, factor, systemic, fibrillation, aspirin, baseline, model, population, Show more, haemostasis pharmacokinetic, nonsteroidal, coadministered, inhibition, biomarkers, effect, activity, treatment regimens, template, significant effects, thromboembolism, development, agents, medications, anti-inflammatory drugs, clinical development, p-gp inhibitors, anti-inflammatory, regimens, significant, results, pharmacology, normalized, systemic exposure, pharmacodynamic, prothrombin time, phase, developed, significantly, population pharmacokinetics, additive, healthy, p-glycoprotein, platelet, nonsteroidal anti-inflammatory drugs, additive effect, data, concentration, thromboplastin, antiplatelet agents, antiplatelet, interactions, thromboplastin time, specific, pharmacodynamic interactions, prothrombin, once-daily, cardiovascular, study, predose, activated, simulations, orally, agent, analyses, systemic embolism, nonsteroidal anti-inflammatory, potential, steady-state, embolism, Show less